SCHEMBL6315515

SCHEMBL6315515

Cc1ccccc1C(=O)Nc1onc(-c2cccs2)c1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 2/20 0.47
THRB P10828 1/20 0.47
FLT3 P36888 1/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
TYK2 P29597 1/20 0.43
CSF1R P07333 1/20 0.43
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 3/20 0.42
KMT2A Q03164 3/20 0.42
HPGD P15428 3/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ABCB1 P08183 1/20 0.42
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318058 0.86 KMT2A (0.54) SMN1; SMN2MAPTTHRBRAB9ANPC1
SCHEMBL6318471 0.84 ALDH1A1 (0.45) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL6317634 0.84 CYP3A4 (0.47) SMN1; SMN2MAPTTHRBFLT3RAB9A
SCHEMBL6314638 0.83 ALDH1A1 (0.54) SMN1; SMN2MAPTFLT3RAB9ANPC1
SCHEMBL6316571 0.83 TYK2 (0.53) SMN1; SMN2MAPTFLT3RAB9ANPC1
SCHEMBL6322761 0.82 FLT3 (0.45) SMN1; SMN2MAPTFLT3RAB9ANPC1
SCHEMBL6318622 0.80 MAPT (0.47) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL6316943 0.80 NPC1 (0.46) SMN1; SMN2MAPTFLT3RAB9ANPC1
SCHEMBL6316470 0.79 RAB9A (0.43) SMN1; SMN2MAPTRAB9ANPC1KDM4E
SCHEMBL6316376 0.79 SMN1; SMN2 (0.50) SMN1; SMN2MAPTFLT3RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885MAPT 281/4885THRB 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.